Is there a retatrutide maintenance dose in the trials?
What the published retatrutide trials call a maintenance dose, what the lowest dose arms reported, and what the class withdrawal trials found. Research context.
Research use only. This page provides scientific background and community-report context. Every compound sold here is supplied strictly for in-vitro research, not for human or veterinary use. Nothing on this page is an application protocol, a recommendation, or medical advice.
TL;DR: trial terminology does not establish a dose reduction strategy
The question people actually type: Is there a retatrutide maintenance dose, or a lowest dose that still works?
What the published data say: Retatrutide papers use “maintenance” for assigned trial doses or the period following escalation. That does not establish a lowest effective dose after weight loss. [PMID 37385280; PMID 41090431]
What the documented search did not identify: No published human trial compares reduced retatrutide maintenance against continued full dosing. A PubMed search on 12 September 2026 returned 11 hits for retatrutide plus maintenance or dose-reduction terms, without that comparison; the dedicated maintenance trial has no posted results. [NCT06859268]
What research communities report: In the Reddit corpus we track, 872 question posts in 12 months, 26 in the 4 to 12 Sept 2026 window matched this pattern. These are reports, not evidence of frequency or a protocol.
What does “maintenance dose” mean in the retatrutide trials?
It means an assigned study dose or a defined treatment period, rather than a proven reduced dose after weight loss. Rosenstock's publication in participants with type 2 diabetes explicitly calls its assigned retatrutide arms “maintenance doses.” The term describes the trial design; it does not identify a dose reduction strategy after an initial response. [PMID 37385280]
The TRIUMPH design paper defines a maintenance period following escalation. That is a planned treatment period, not a published result establishing how little retatrutide would preserve an earlier weight change. [PMID 41090431]
The same protocols permit a permanent dose reduction only for named reasons, among them gastrointestinal adverse events or inadequate oral intake that has not improved with other mitigations. A protocol allowance for managing these problems is different from a randomized comparison showing that a reduced dose preserves the original response. [PMID 41090431]
What did the lowest dose arms report?
The lowest arms reported different findings in different trial populations and at different endpoints. In the phase 2 trial involving participants with type 2 diabetes, the retatrutide 0.5 mg arm received once-weekly subcutaneous injections and reported HbA1c change of -0.43% at week 24 versus -0.01% with placebo, without statistically significant separation; weight change at week 36 was -3.19% versus -3.00%. The route is also documented in the substudy of the same trial. These findings concern that assigned arm, not a maintenance threshold. [PMID 37385280; PMID 40609566; NCT04867785]
These are the study arms of the cited trials, not an application protocol for research vials.
In the phase 2 obesity trial, participants assigned to the retatrutide 1 mg arm received subcutaneous treatment once weekly for 48 weeks; the reported least-squares mean percentage weight change was -8.7%, compared with -2.1% for placebo. This was an assigned treatment arm, not a group switched to a lower dose after an initial response. [PMID 37366315; NCT04881760]
The table keeps the comparator and observation window attached to each result. Its rows summarize the arms described above, rather than stages in a schedule.
- Reported weight change
- -3.19%
- Placebo comparator
- -3.00%
- Observation window and source
- Week 36, PMID 37385280
- Reported weight change
- -8.7%
- Placebo comparator
- -2.1%
- Observation window and source
- Week 48, PMID 37366315
The trials therefore answer what those assigned arms reported during treatment. They do not establish an individual minimum, and a numerical change within an arm is not itself evidence of separation from placebo. The diabetes publication explicitly reports the lack of significant HbA1c separation in its lowest arm. [PMID 37385280; PMID 37366315]
Has a trial tested lowering retatrutide after the initial response?
No published human trial reports the comparison of a reduced maintenance dose against continued full dosing. The PubMed search dated 12 September 2026 used retatrutide AND (maintenance dose OR dose reduction OR de-escalation OR lowest effective dose) and returned 11 hits, comprising phase 2 trials, substudies, reviews, or meta-analyses rather than that comparison.
A dedicated phase 3b maintenance trial is active but no longer recruiting. Its registry describes continuation, a dose switch, and a switch to placebo after an initial treatment period. It lists 643 participants, completion in April 2028, and no posted results in the registry retrieval of 12 September 2026. There are therefore no human results from this trial to quote for dose reduction or withdrawal. [NCT06859268]
Where the evidence stops
Whether to lower, space or stop a dose is a clinical decision. An unfinished comparison cannot establish a retatrutide maintenance recommendation, and results with other compounds cannot supply the missing retatrutide result. [NCT06859268]
What do withdrawal trials of related medicines report?
Tirzepatide and semaglutide withdrawal trials reported weight regain after switching to placebo or stopping treatment; these are class comparisons, not retatrutide findings. [PMID 38078870; PMID 33755728; PMID 35441470] PeptidesDirect does not sell tirzepatide. PeptidesDirect does not sell semaglutide.
In Aronne's randomized tirzepatide withdrawal trial, participants who continued treatment had a mean weight change of -5.5% from week 36 to week 88, compared with +14.0% among those switched to placebo. This compared continuation with withdrawal, not a reduced retatrutide arm with a continued full-dose arm. [PMID 38078870; NCT04660643]
Rubino's semaglutide trial reported -7.9% with continuation versus +6.9% after switching to placebo from week 20 to week 68. In Wilding's exploratory semaglutide extension, participants regained 11.6 percentage points of lost weight by week 120 after treatment stopped at week 68, while the placebo group regained 1.9 points. These findings explain the relevance of withdrawal research without quantifying what happens after retatrutide withdrawal. [PMID 33755728; PMID 35441470]
Do approved labels settle the retatrutide maintenance question?
No. The approved US labels for WEGOVY, containing semaglutide, and ZEPBOUND, containing tirzepatide, name maintenance dosages for those medicines. Their label terminology is a regulatory contrast, not evidence for a retatrutide maintenance dose. [WEGOVY US PI, section 2.2; ZEPBOUND US PI, section 2.2]
Retatrutide has no approved US product label; the DailyMed search of 12 September 2026 returned no approved retatrutide label. The monotherapy publication describes it as under clinical development; maintenance wording in a paper does not change that status. The unresolved question remains whether a reduced retatrutide arm preserves an earlier response compared with continued full dosing. [PMID 42250575; NCT06859268]
Products mentioned
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide that acts on three receptors at once: GLP-1, GIP and glucagon. Supplied as a lyophilized powder for in-vitro research, with a batch-specific third-party certificate of analysis.
Sources
- Rosenstock, 2023. Phase 2 type 2 diabetes publication. Lancet 402:529-544. PMID 37385280; NCT04867785.
- Jastreboff, 2023. Phase 2 obesity trial. N Engl J Med 389:514-526. PMID 37366315; NCT04881760.
- Giblin, 2026. TRIUMPH design paper. Diabetes Obes Metab. PMID 41090431; PMC12673447.
- ClinicalTrials.gov, retrieved 12.09.2026. Retatrutide maintenance trial registry entry. NCT06859268.
- Aronne, 2024. Tirzepatide withdrawal trial. JAMA 331:38-48. PMID 38078870; NCT04660643.
- Rubino, 2021. Semaglutide continuation versus placebo. JAMA 325:1414-1425. PMID 33755728; NCT03548987.
- Wilding, 2022. Semaglutide exploratory extension. Diabetes Obes Metab 24:1553-1564. PMID 35441470; NCT03548935.
- DailyMed, retrieved 12.09.2026. WEGOVY (semaglutide) US PI, section 2.2. Setid ee06186f-2aa3-4990-a760-757579d8f77b.
- DailyMed, retrieved 12.09.2026. ZEPBOUND (tirzepatide) US PI, section 2.2. Setid 487cd7e7-434c-4925-99fa-aa80b1cc776b.
- Bajaj, 2026. Phase 3 monotherapy trial. Lancet 407:2402-2413. PMID 42250575; NCT06354660.
- Coskun, 2025. Substudy of the type 2 diabetes trial, administration route. Lancet Diabetes Endocrinol 13:674-684. PMID 40609566; NCT04867785.
Research use only. Retatrutide is supplied strictly for in-vitro laboratory research, not for human or veterinary use. Nothing here is an application protocol, a recommendation, or medical advice.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include VAT, the rate depends on the destination country; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.